Kunhwa Kim

662 total citations
22 papers, 327 citations indexed

About

Kunhwa Kim is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Kunhwa Kim has authored 22 papers receiving a total of 327 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 9 papers in Oncology and 6 papers in Genetics. Recurrent topics in Kunhwa Kim's work include Acute Myeloid Leukemia Research (11 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Acute Lymphoblastic Leukemia research (3 papers). Kunhwa Kim is often cited by papers focused on Acute Myeloid Leukemia Research (11 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Acute Lymphoblastic Leukemia research (3 papers). Kunhwa Kim collaborates with scholars based in United States, Japan and China. Kunhwa Kim's co-authors include Marina Konopleva, Koji Sasaki, Hagop M. Kantarjian, Farhad Ravandi, Nicholas J. Short, Koichi Takahashi, Musa Yılmaz, Tapan M. Kadia, Naval Daver and Courtney D. DiNardo and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Kunhwa Kim

19 papers receiving 327 citations

Peers

Countries citing papers authored by Kunhwa Kim

Since Specialization

Citations

This map shows the geographic impact of Kunhwa Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kunhwa Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kunhwa Kim more than expected).

Fields of papers citing papers by Kunhwa Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kunhwa Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kunhwa Kim. The network helps show where Kunhwa Kim may publish in the future.

Co-authorship network of co-authors of Kunhwa Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Kunhwa Kim. A scholar is included among the top collaborators of Kunhwa Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kunhwa Kim. Kunhwa Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor 2025 ·Haematologica ·Nicholas J. Short, Sanam Loghavi, Musa Yılmaz, (unknown), Kunhwa Kim, Courtney D. DiNardo, Tapan M. Kadia, (unknown), Gautam Borthakur, Ghayas C. Issa, (unknown), Betül Oran, Elizabeth J. Shpall, Uday Popat, Keyur P. Patel, Mark J. Routbort, Marina Konopleva, Farhad Ravandi, Hagop Kantarjian, Naval Daver	0
2	Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes 2025 ·Blood ·Kelly S. Chien, Ziyi Li, (unknown), (unknown), Kunhwa Kim, (unknown), Rashmi Kanagal‐Shamanna, Guillermo Montalban‐Bravo, (unknown), Elias Jabbour, Naveen Pemmaraju, Danielle Hammond, Nicholas J. Short, Farhad Ravandi, (unknown), Sherry Pierce, (unknown), Hui Yang, Hagop M. Kantarjian, Guillermo Garcia-Manero	0
3	Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma 2024 ·Blood ·Kunhwa Kim, Dai Chihara, Luis Fayad, Sattva S. Neelapu, Sairah Ahmed, Frederick Hagemeister, (unknown), Swaminathan P. Iyer, Preetesh Jain, Michael Wang, Paolo Strati, Fateeha Furqan, (unknown), Michael R. Green, Christopher R. Flowers, Jason R. Westin	2
4	Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms 2024 ·Cancer Medicine ·Kelly S. Chien, (unknown), Kunhwa Kim, Ziyi Li, Rashmi Kanagal‐Shamanna, Courtney D. DiNardo, Koichi Takahashi, Guillermo Montalban‐Bravo, Danielle Hammond, Koji Sasaki, Sherry Pierce, Hagop M. Kantarjian, Guillermo Garcia‐Manero	5
5	Current Understanding of DDX41 Mutations in Myeloid Neoplasms 2023 ·Cancers ·Kunhwa Kim, (unknown), Koji Sasaki	12
6	Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes 2022 ·American Journal of Hematology ·(unknown), Kunhwa Kim, Rashmi Kanagal‐Shamanna, Gautam Borthakur, Guillermo Montalban‐Bravo, Naval Daver, Courtney D. DiNardo, Nicholas J. Short, Musa Yılmaz, Naveen Pemmaraju, Koichi Takahashi, Elias Jabbour, Sherry Pierce, Marina Konopleva, Kapil N. Bhalla, Guillermo Garcia‐Manero, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia	17
7	Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials 2022 ·American Journal of Hematology ·Kunhwa Kim, Marina Konopleva, Courtney D. DiNardo, Gautam Borthakur, Sanam Loghavi, Guilin Tang, Naval Daver, Naveen Pemmaraju, Elias Jabbour, Caitlin R. Rausch, Musa Yılmaz, Koji Sasaki, Nicholas J. Short, Nitin Jain, Mark Brandt, Sherry Pierce, Guillermo Garcia‐Manero, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia	6
8	Venetoclax resistance: mechanistic insights and future strategies 2022 ·Cancer Drug Resistance ·(unknown), Kunhwa Kim, Marina Konopleva	66
9	More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia 2022 ·Blood ·Fadi Haddad, Koji Sasaki, Ghayas C. Issa, Kunhwa Kim, Jeffrey Skinner, Sara Dellasala, Yesid Alvarado, Alessandra Ferrajoli, Tapan M. Kadia, Musa Yılmaz, Naveen Pemmaraju, Guillermo Garcia‐Manero, Sherry Pierce, Elias Jabbour, Hagop Kantarjian	2
10	MDS-431 Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes 2022 ·Clinical Lymphoma Myeloma & Leukemia ·Kunhwa Kim, (unknown), Ziyi Li, Rashmi Kanagal‐Shamanna, Guillermo Montalban‐Bravo, Tapan M. Kadia, Elias Jabbour, Naveen Pemmaraju, Danielle Hammond, Nicholas J. Short, Farhad Ravandi, Yesid Alvarado, Sherry Pierce, (unknown), Hagop M. Kantarjian, Guillermo Garcia‐Manero, Kelly S. Chien	1
11	Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax 2021 ·Cancer ·Kunhwa Kim, Abhishek Maiti, Sanam Loghavi, Rasoul Pourebrahim, Tapan M. Kadia, Caitlin R. Rausch, Ken Furudate, Naval Daver, Yesid Alvarado, Maro Ohanian, Koji Sasaki, Nicholas J. Short, Koichi Takahashi, Musa Yılmaz, Guilin Tang, Farhad Ravandi, Hagop M. Kantarjian, Courtney D. DiNardo, Marina Konopleva	100
12	Current Approaches to Philadelphia Chromosome–Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant 2021 ·Current Oncology Reports ·Kunhwa Kim, Elias Jabbour, Nicholas J. Short, Partow Kebriaei, Hagop M. Kantarjian, Farhad Ravandi	7
13	The Prognostic Implication of Adult Comorbidity Evaluation 27 Score in CML Patients on Tyrosine-Kinase Inhibitors 2021 ·Blood ·Kunhwa Kim, Hagop M. Kantarjian, Elias Jabbour, Ghayas C. Issa, Farhad Ravandi, Courtney D. DiNardo, Marina Konopleva, Nitin Jain, Naveen Pemmaraju, Gautam Borthakur, Tapan M. Kadia, Guillermo Garcia‐Manero, Kiyomi Morita, Sherry Pierce, Jörge E. Cortes, Koji Sasaki	2
14	Contemporary outcomes for adults with AML requiring ICU admission. 2021 ·Journal of Clinical Oncology ·Danielle Hammond, Koji Sasaki, (unknown), Fadi Haddad, Shehab Mohamed, (unknown), (unknown), (unknown), (unknown), Kiyomi Morita, Kunhwa Kim, Sherry Pierce, Cristina Gutiérrez, Naveen Pemmaraju, Gautam Borthakur, Courtney D. DiNardo, Farhad Ravandi, Guillermo Garcia‐Manero, Hagop M. Kantarjian, Tapan M. Kadia	3
15	Dose intensity of nab-paclitaxel and gemcitabine chemotherapy in metastatic pancreatic cancer. 2019 ·Journal of Clinical Oncology ·(unknown), Dae Won Kim, Kunhwa Kim, Richard D. Kim, (unknown)	4
16	Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study 2018 ·Cancer Epidemiology ·Kunhwa Kim, (unknown), Carol J. Etzel, Jinhyun Kim, Hyunjin Ryu, Dae Won Kim, Patrick Hwu, Wen-Jen Hwu, Sapna P. Patel, Mei Liu, Kevin B. Kim	6
17	Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies In Vivo 2017 ·Clinical Cancer Research ·Hong Qin, Guo‐Wei Wei, Ippei Sakamaki, Zhenyuan Dong, Wesley A. Cheng, D. Lynne Smith, Feng Wen, Han Sun, Kunhwa Kim, (unknown), Laura Bover, Sattva S. Neelapu, Larry W. Kwak	24
18	Understanding Hearing Loss and Barriers to Hearing Health Care Among Korean American Older Adults: A Focus Group Study 2016 ·Journal of Applied Gerontology ·Janet S. Choi, (unknown), Kunhwa Kim, Carrie L. Nieman, Sara K. Mamo, Frank R. Lin, Hae‐Ra Han	23
19	Clinical characteristics of patients with non-V600 BRAF mutant melanomas. 2014 ·Journal of Clinical Oncology ·Daewon Kim, (unknown), Kunhwa Kim, Michael A. Davies, Mark J. Routbort, Alexander J. Lazar, (unknown), Alan Siroy, Agop Y. Bedikian, Nicholas E. Papadopoulos, Wen‐Jen Hwu, Patrick Hwu, Scott E. Woodman, Sapna P. Patel, Kevin Kim	3
20	Nonstereotyped Lymphoma B Cell Receptors Recognize Vimentin as a Shared Autoantigen 2013 ·The Journal of Immunology ·Soung-Chul Cha, Hong Qin, Shibichakravarthy Kannan, Seema Rawal, (unknown), (unknown), Weiguo Wu, (unknown), (unknown), (unknown), Sang Kim, (unknown), (unknown), Kunhwa Kim, Amber Luong, R. Eric Davis, Harry W. Schroeder, Larry W. Kwak, Sattva S. Neelapu	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact